NCT07920731
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Progression-free survival (PFS)
Timeframe: From first antitumor treatment until disease progression or death from any cause, whichever occurs first; assessed throughout treatment and survival follow-up, up to 24 months after the last patient is enrolled
Arms and interventions
imotuzumab combined with the NALIRIFOX chemotherapyOther
Drugs: imotuzumab combined with the NALIRIFOX chemotherapy
Sites
1 site in 1 country
- FUSCCShanghai, Shanghai Municipality, China